BOSTON MEDICAL CENTER
HEALTHNet PLAN

bmchp.org | 888-566-0008

Pharmacy Policy

Ilumya™

Policy Number: 9.149
Version Number: 2.1
Version Effective Date: 3/1/2022

Product Applicability ☐ **All Plan+ Products**

Well Sense Health Plan
☐ New Hampshire Medicaid

Boston Medical Center HealthNet Plan
☐ MassHealth - MCO
☐ MassHealth - ACO
☒ Qualified Health Plans/ConnectorCare/Employer Choice Direct
☐ Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

Prior Authorization Policy

Products Affected:

Ilumya™ (tildrakizumab-asmn for subcutaneous injection

The Plan may authorize coverage of the above products for members meeting the following criteria:

Covered Use	All FDA approved indications not otherwise excluded
Required Medical Information	**<u>Plaque Psoriasis</u>** Member must meet the following (i, ii, and iii): i. The member is ≥ 18 years of age; **AND** ii. Ilumya is prescribed by or in consultation with a dermatologist; **AND** iii. Documentation* that the member has tried TWO of the following Enbrel, Humira, Otezla, Skyrizi, Stelara subcutaneous, Taltz, or Tremfya. * Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts

+ *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Age Restriction	18 years and older
Prescriber Restriction	Prescribed by or in consultation with a dermatologist
Coverage Duration	Initial – 3 months Reauthorization - 1 year
Reauthorization criteria	Reauthorization Criteria: i. Initial criteria are met; **AND** ii. Member's clinical condition has improved or stabilized

Applicable Coding:

Code	Medication
J3245	Injection, tildrakizumab-asmn, 1mg

Clinical Background Information and References

1. American Academy of Dermatology Association. Psoriasis Clinical Guideline. https://www.aad.org/member/clinical-quality/guidelines/psoriasis. Accessed July 2021.
2. Ilumya (tildrakizumab-asmn) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; March 2021.
3. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.

Original Approval Date	Original Effective Date	Policy Owner	Approved by
5/24/2021	7/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History			
Review Date	**Summary of Revisions**	**Revision Effective Date**	**Approved by**
5/24/2021	Policy created	7/1/2021	P&T Committee

[+] *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Policy Revisions History			
8/12/2021	Annual P&T Review: No recommended changes.	1/1/2022	P&T Committee
1/20/2022	Updated to realign with ESI ICCV policy	3/1/2022	P&T Committee

Next Review Date

8/2022

Other Applicable Policies

Reference to Applicable Laws and Regulations, If Any

Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

[+] *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.